{
    "2018-03-28": [
        [
            {
                "time": "2018-01-01",
                "original_text": "How Bristol-Myers Squibb’s Oncology Drugs Performed in 4Q17",
                "features": {
                    "keywords": [
                        "Bristol-Myers Squibb",
                        "Oncology Drugs",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "A Look at Bristol-Myers Squibb’s 4Q17 Revenue",
                "features": {
                    "keywords": [
                        "Bristol-Myers Squibb",
                        "Revenue",
                        "4Q17"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "How Novartis’s Oncology Segment Drugs Are Performing",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Oncology Segment",
                        "Drugs"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "Bristol-Myers Squibb’s Valuation in March 2018",
                "features": {
                    "keywords": [
                        "Bristol-Myers Squibb",
                        "Valuation",
                        "March 2018"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy",
                "features": {
                    "keywords": [
                        "FDA",
                        "Bristol-Myers",
                        "Colorectal Cancer",
                        "Combo Therapy"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "3 Biotechs That Could Get Big Boosts in April",
                "features": {
                    "keywords": [
                        "Biotechs",
                        "Big Boosts",
                        "April"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "Biotech Stocks Facing FDA Decision In April",
                "features": {
                    "keywords": [
                        "Biotech Stocks",
                        "FDA Decision",
                        "April"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}